Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics

Radiolabeled gastrin-releasing peptide receptor (GRPR) antagonists have shown great promise for the theranostics of prostate cancer; however, their suboptimal metabolic stability leaves room for improvements. It was recently shown that the replacement of Gly(11) with Sar(11) in the peptidic [D-Phe(6...

Descripción completa

Detalles Bibliográficos
Autores principales: Abouzayed, Ayman, Kanellopoulos, Panagiotis, Gorislav, Alisa, Tolmachev, Vladimir, Maina, Theodosia, Nock, Berthold A., Orlova, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377574/
https://www.ncbi.nlm.nih.gov/pubmed/37509170
http://dx.doi.org/10.3390/biom13071134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377574/
https://www.ncbi.nlm.nih.gov/pubmed/37509170
http://dx.doi.org/10.3390/biom13071134

Ejemplares similares